| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24018 |
| Drug | Relugolix with estradiol and norethisterone acetate |
| Brand | Ryeqo® |
| Indication | Relugolix with estradiol and norethisterone acetate (Ryeqo®) is Indicated in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. |
| Assessment Process | |
| Rapid review commissioned | 28/05/2024 |
| Rapid review completed | 15/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of relugolix combination therapy compared with the current standard of care. |
| Full HTA commissioned by the HSE | 31/07/2024 |
| Pre-submission consultation with Applicant | 18/02/2025 |
| Full submission received from Applicant | 15/07/2025 |
| Preliminary review sent to Applicant | 29/01/2026 |
| NCPE assessment re-commenced | 10/03/2026 |
| Factual accuracy sent to Applicant | 08/04/2026 |
| NCPE assessment re-commenced | 16/04/2026 |
| NCPE assessment completed | 28/04/2026 |
| NCPE assessment outcome | The NCPE recommends that relugolix CT (Ryeqo®) not be considered for reimbursement, for this indication, unless cost-effectiveness can be improved relative to existing treatment |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE
when making their decision on reimbursement, while also having regard to the criteria specified
in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.